Mechanism of Action

Indication
CIMZIA is indicated for the treatment of adults with moderate to severe rheumatoid arthritis (RA).

Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

*The CIMZIA Co-pay Savings Card program is valid for out-of-pocket expenses for CIMZIA for up to 17 uses. The CIMZIA Co-pay Savings Card program is not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

Reference:

1. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc., 2011.

SITEMAP

For U.S. Healthcare Professionals

© 2012 UCB, Inc. All rights reserved.
CCR035-1211B

• CIMZIA.com|
• Medication Guide & Prescribing Information|
• Privacy Policy|
• Terms of Use|
• About UCB|
• Contact Us|
• Unsubscribe

CIMZIA^®, CIMplicity™, CIMpay^® are trademarks of the UCB Group of Companies.
OXO, Good Grips, and the associated logos are trademarks of Helen of Troy Limited and are used under license.